Assessing the risks for perinatal infection. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Assessing the risks for perinatal infection. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

AIDS Alert. 1995 Apr;10(4):56. Unique Identifier : AIDSLINE AIDS/95700227

Abstract: The Centers for Disease Control and Prevention (CDC) recently conducted a review of 5,554 cases of children with perinatally acquired AIDS through December 1994 in order to determine the risks of perinatally acquired AIDS. CDC epidemiologist Teresa Hammett reported at the HIV Infection in Women: Setting A New Agenda conference in Washington, DC, that the data showed a significant risk of perinatal infection from women who were injection drug users or had heterosexual contact with a known drug user. Hammett also said that a maternal risk study currently is under way that evaluates information on the mother's medical record and/or information obtained through discussion with the mother. Programs that target mothers and their partners at high risk must be culturally and linguistically appropriate. The CDC, as part of its AIDS surveillance data analysis, also plans to implement studies of HIV risk behaviors among more recently infected women, and women with sexually transmitted diseases.
Keywords: Acquired Immunodeficiency Syndrome/*TRANSMISSION *Disease Transmission, Vertical Female Human Pregnancy Pregnancy Complications, Infectious Substance Abuse, Intravenous/*COMPLICATIONS NEWSLETTER ARTICLE REVIEWKWDacquiredimmunodeficiencysyndrome/KWDtransmissionKWDdiseasetransmission,verticalfemalehumanpregnancypregnancycomplications,infectioussubstanceabuse,intravenous/KWDcomplicationsnewsletterarticlereview
951030
M95A0957

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .